KMDA
Kamada Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$8.54
+3.26%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
17.2x
EV/EBITDA
10.3x
Market Cap
$492.71M
MomentumView details →
1D Return
+3.26%
YTD Return
+20.40%
RSI (14)
66.2
ValuationView details →
P/E (Fwd)
17.2x
EV/EBITDA
10.3x
Market Cap
$492.71M
RSI (14)
66.2
MomentumView details →
1D Return
+3.26%
YTD Return
+20.40%
SummaryUpdated Jun 1, 2026
Kamada Ltd. (NASDAQ:KMDA) is an Israeli biopharmaceutical company founded in 1990 and headquartered in Rehovot, Israel. The company went public on NASDAQ in 2013 and has transformed from a single-product dependency into a diversified plasma-derived therapeutics company. Kamada specializes in developing, manufacturing, and commercializing plasma-derived protein therapeutics, primarily targeting rare diseases and immune-related conditions. The company operates through two main business segments: Proprietary Products and Distribution, with a growing focus on the U.S. market which now represents approximately 60-70% of its revenues.
Similar companies
Latest newsMore news →
Kamada Ltd. obtained a tax ruling from the Israel Tax Authority regarding its previously announced cash dividend of $0.17 per share, totaling approximately $9.8 million, to be paid on September 17, 2026.1d agoKamada declared a cash dividend of $0.17 per share, to be paid consistent with its cash dividend policy, alongside reporting record-high revenue and profitability for the first six months of 2026.19d agoKamada Ltd. reported record-high financial results for the second quarter and first half of 2026, with double-digit profitable growth, and affirmed its 2026 annual guidance.24d ago